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Abstrak 
 
Penilaian penguraian radioaktif iodin di kalangan pesakit “differentiated 
thyroid carcinoma” di Hospital Kuala Lumpur. 
 
Pendahuluan: Rawatan radioaktif iodin telah lama digunakan sejak tahun 1950-
an lagi untuk merawat pelbagai jenis penyakit barah dan penyakit bukan barah. 
Ia adalah jenis rawatan yang paling popular, digunakan secara meluas, efektif 
dan selamat bagi kategori bahan radio aktif terapi yang tidak bertutup. Walau 
bagaimanapun, disebabkan oleh sinaran “gamma” yang dipancarkan olehnya 
yang boleh merangsang kesan sampingan “stochastic” terhadap orang awam 
regulasi radiasi untuk I-131 telah diperkenalkan. Setiap negara ada regulasi 
masing-masing bagi menentukan tempoh isolasi yang sesuai sebelum pesakit 
dibenarkan pulang. Akta Perlesenan Tenaga Atom 1984  (Akta 304) telah 
menetapkan pesakit hanya dibenarkan pulang apabila pancaran kadar radiasi di 
bawah aras 50µSv/H, atau bersamaan 1100MBq jumlah aktiviti radiasi di dalam 
badan. 
 
Tujuan: Untuk mengkaji tempoh pengasingan yang sesuai bagi pesakit kanser 
tiroid yang menerima rawatan radio aktif iodin di Hospital Kuala Lumpur. 
 
Metodologi:  Pesakit barah tiroid jenis “differentiated” yang dirujuk bagi tujuan 
rawatan radioaktif iodin telah diambil sebagai pesakit untuk penyelidikan.  Jumlah 
 xiii 
semua pesakit adalah 170 orang dan mereka dibahagikan kepada 4 kumpulan 
mengikut jumlah iodin yang diterima (80mCi, 100mCi, 120mCi and 150mCi). 
Kadar pancaran radiasi diukur pada 6, 18, 24, 48 and 72 jam selepas pesakit 
menerima rawatan menggunakan “ionising chamber survey meter”. Graf kadar 
radiasi dengan masa dicipta dan segala maklumat klinikal dianilisis 
menggunakan perisian IBM SPSS. 
 
Keputusan: Purata separuh masa penguraian iodin ialah 14.57±1.03 jam iaitu 
bersamaan dengan 14 jam 34 minit. Faktor jantina dan dos iodin yang diberikan 
mempengaruhi kadar penguraian iodin, masing-masing menunjukkan nilai 
p=0.006 dan p<0.001. Manakala, tiada perbezaan ketara kadar penguraian iodin 
jika dibandingkan dengan faktor jenis kanser tiroid, bangsa dan umur. Sebanyak 
167 orang daripada 170 orang (98.2%) mempunyai kadar radiasi di bawah paras 
50µSv pada 48 jam. 
 
Kesimpulan: Tempoh pengasingan yang ideal bagi rawatan iodin untuk pesakit 
tiroid di Hospital Kuala Lumpur yang mempunyai fungsi buah pinggang yang 
normal tanpa mengira bangsa, dos iodin yang diterima, jantina dan umur ialah 
48jam. 
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Abstract 
 
Assessment of radioiodine clearance in differentiated thyroid cancer 
patients in Hospital Kuala Lumpur.  
 
Introduction: Radioiodine treatment has long been used since 1950’s for the 
treatment of various malignancy and non-malignancy diseases. It was the most 
popular, widely used, effective and safe unsealed source of radionuclide therapy. 
However, due to high gamma energy emitted from it which may induce stochastic 
effect to the public, radiation regulation has been introduced. Different countries 
have their own regulation regarding period of hospitalization needed before 
patient can be released to the public. Atomic Energy Licensing Act 1984 (Act 304) 
has stated that patient shall be discharged from isolation once the external dose 
rate falls below 50µSv/H which is equal to retained body activity of 1100MBq.  
 
Aim: To assess the appropriate isolation period of radioactive iodinated thyroid 
cancer patients in Hospital Kuala Lumpur. 
 
Material and methods: Differentiated thyroid cancer patients referred for 
radioactive iodine treatment were recruited in this study. Total participants were 
170 and divided into 4 groups based on I-131 doses given (80mCi, 100mCi, 
120mCi and 150mCi). External dose rate was measured at 6, 18, 24, 48 and 72 
hours after ingestion of I-131 using ionising chamber survey meter. Graph of 
 xv 
radioactivity versus time was plotted and clinical data was analysed using IBM 
SPSS software. 
 
Results: Mean effective half-life of I-131 is 14.57±1.03 hours which is equal to 
14 hours and 34 minutes. Initial dose of I-131 and gender had significantly 
influenced iodine clearance with p value of 0.006 and <0.001 respectively. 
Conversely, the types of thyroid cancer, races and age do not have significant 
impact on iodine clearance. One hundred and sixty seven out of 170 patients 
(98.2%) had radiation level below 50µSv at 48 hours. 
 
Conclusion: Ideal isolation period for I-131 treatment for thyroid cancer patient 
with normal renal function in Hospital Kuala Lumpur regardless of ethnics, iodine 
doses, gender and ages is 48 hours. 
 
Keyword: Differentiated thyroid carcinoma, iodine-131, effective half-life, patient 
discharge, external dose rate, radiation safety. 
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CHAPTER ONE 
RESEARCH BACKGROUND 
1.1 Introduction 
             Approximately 5% of women and 1% of men worldwide have thyroid nodule 
diseases. These nodules have possibility to progress into malignancy in about 5-
15%. Risk of thyroid cancer increased with history of head, neck and total body 
irradiation; strong family history of thyroid cancer, hoarseness of voice, rapid growth 
of the nodule and FDG avidity of thyroid nodule (American Thyroid Association 
Guidelines Taskforce on Thyroid et al., 2009; Haugen et al., 2016). 
            Thyroid cancer attributes to 1% of total malignancy and the most common 
endocrine malignancy. The incidence of thyroid cancer all over the globe has been 
increasing over the last decade due to improvement of imaging modalities to detect 
even thyroid microcarcinoma (<1cm) and rising in public awareness towards thyroid 
cancer itself.  Majority of thyroid cancer cases were differentiated thyroid cancer 
(DTC) (90%) followed by medullary thyroid cancer (5-8%), poorly differentiated 
thyroid cancer (1-6%) and anaplastic thyroid cancer. Among all of them, DTC has a 
good response towards treatment and better prognosis and survival rate (F. Pacini, 
2012). 
            DTC is further divided into papillary (85%), follicular (10%), Hurtle and oxyphil 
subtypes (3%). Papillary subtype tends to spread through lymphatic chain while 
follicular disseminated through blood supply. Hurtle subtype is variant of papillary 
thyroid carcinoma but behaves like follicular variant (Nuclear Oncology: 
Pathophysiology and Clinical Applications, 2012; The Pathophysiologic Basis of 
Nuclear Medicine, 2006; Ziessman et al., 2013). All these variants expressed TSH 
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receptor on the cell membrane (sodium iodide symporter) which responds towards 
TSH stimulation by increasing thyroid specific protein secretion (thyroglobulin) and 
also speed up the rate of cancer cells growth (American Thyroid Association 
Guidelines Taskforce on Thyroid et al., 2009; Haugen et al., 2016). 
            Patients who are having DTC are stratified into 3 groups (high, intermediate 
and low risk) based on HPE, completion of surgery, serum TG, metastasis and 
Iodine WBS findings (table 1.1). All thyroid cancer guidelines agreed that high risk 
patient should undergo total or near total thyroidectomy followed by radioactive 
iodine (RAI) and TSH suppression therapy. These will improve in disease prognosis, 
reducing rate of recurrences and improve overall survival. On the other hand, 
remnant ablation may be indicated to intermediate risk patient whereas it is not 
necessary (weak recommendation) in low risk patient. Nearly 70% of loco-regional 
lymphadenopathies and pulmonary micro metastasis successfully cured with RAI 
treatment (F. Pacini, 2012; Haugen et al., 2016; Perros et al., 2014; Watkinson and 
British Thyroid, 2004).   
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Table 1.1 ATA 2009 Risk Stratification System with Proposed Modifications 
(Source: 2015 American Thyroid Association Management Guidelines for Adult 
Patients with Thyroid Nodules and Differentiated Thyroid Cancer).  
 
Low risk Papillary thyroid cancer (with all of the following):  
a)  No local or distant metastases;   
b)  All macroscopic tumour has been resected   
c) No tumour invasion of loco-regional tissues or structures   
d) The tumour does not have aggressive histology (e.g., tall 
cell, hobnail variant, columnar cell carcinoma)   
e) If  131I is given, there are no RAI-avid metastatic foci outside 
the thyroid bed on  the first posttreatment whole-body RAI 
scan. 
f) No vascular invasion   
Intrathyroidal, encapsulated follicular variant of papillary thyroid 
cancer 
Intrathyroidal, well differentiated follicular thyroid cancer with 
capsular invasion and no or minimal (<4 foci) vascular invasion. 
Intrathyroidal, papillary microcarcinoma, unifocal or multifocal, 
including BRAFV600E mutated. 
 4 
Intermediate 
risk 
Microscopic invasion of tumour into the perithyroidal soft tissues  
RAI-avid metastatic foci in the neck on the first post-treatment 
whole-body RAI scan  
Aggressive histology (e.g., tall cell, hobnail variant, columnar cell 
carcinoma)  
Papillary thyroid cancer with vascular invasion  
Clinical N1 or >5 pathologic N1 with all involved lymph nodes <3 
cm in largest dimension 
Multifocal papillary microcarcinoma with ETE and BRAFV600E 
mutated. 
High risk  Macroscopic invasion of tumour into the perithyroidal soft tissues 
(gross ETE).  
Incomplete tumour resection.  
Distant metastases. 
Postoperative serum thyroglobulin suggestive of distant 
metastases Pathologic N1 with any metastatic lymph node >3 cm 
in largest dimension. 
Follicular thyroid cancer with extensive vascular invasion (> 4 foci 
of vascular invasion) . 
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Aims of RAI therapy (Haugen et al., 2016; Perros et al., 2014; Zhang et al., 2014): 
I. To improve and prolong patient survival. 
II. To reduce risk of local and distant tumour recurrence by eradicating 
residual microscopic tumour foci and thyroid tissue post operatively. 
III. To provide reassurance to patients that they are free of disease with 
undetectable serum thyroglobulin (TG), negative clinical examination and 
negative finding of imaging modalities (USG and thyroid WBS).   
IV. Increased sensitivity of TG monitoring facilitating early detection of 
recurrence or metastatic disease.                
             I-131 is produced in nuclear reactor by fission of uranium atom. It decays 
into Xe-131 by emission of Beta (606 KeV) and Gamma (364 KeV) energies. The 
physical half-life of the radionuclide is 8 days. The b-energy emitted with mean range 
in soft tissue of 0.4 mm is responsible for the therapeutic effect by inducing damage 
to the follicular cells by direct damage to DNA and free radical formation. This will 
result in cell apoptosis in the autonomous functioning thyroid tissues. Meanwhile γ-
energy is used for imaging purposes and calculation of the radioiodine thyroid uptake 
ratio (Bonnema and Hegedus, 2012). 
           Even though International Atomic Energy Agency (IAEA) and International 
Commission on Radiological Protection (ICRP) has stated that there is no dose limit 
to patients, the maximum permissible doses can be prescribed are limited to the 
absorbed dose of I-131 to bone marrow and radioactivity retention in the lung. In 
general, the range of radioactive iodine treatment activity is between 1.1GBq up to 
11.1GBq (30-300mCi) (Ravichandran, 2014; Release of Patients After Radionuclide 
Therapy, 2009; Willegaignon et al., 2006). Absolute contraindications for I-131 
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therapy are pregnancy and breastfeeding while relative contraindication includes 
urinary incontinence and patient who is unable to follow regulation safety post iodine 
treatment. 
           After ingestion of I-131, up to 90% of iodine will be reduced to iodide in 
proximal small bowel within one hour. These iodides are trapped by follicular cell by 
high energy sodium iodide symporter and will be concentrated 25-500 times greater 
than plasma level. After that, it will be oxidized to iodine by thyroxine peroxidase, 
which binds to tyrosine residues on thyroglobulin. These monoiodinate and diodinate 
are coupled to form triiodothyronine (T3) and thyroxine (T4) and stored in colloid. 
Radioiodine is metabolised in the liver and muscle (The Pathophysiologic Basis of 
Nuclear Medicine, 2006; Release of Patients After Radionuclide Therapy, 2009; 
Ziessman et al., 2013). 
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Figure 1.1 Metabolism of I-131 (Source: Nuclear Medicine,The Requisites 4th 
edition). 
 
            
Many factors may influence retention of I-131 in the body such as renal 
function, TSH stimulation, amount of thyroid tissue, metastatic foci, diet, age, body 
mass, gender and race. I-131 is rapidly excreted from the body in the first 48 hours 
by urine which attributed to more than 80% of I-131 clearance, whereas up to 6% 
through feces and insignificant clearance through sweat, saliva and exhalation.  
(American Thyroid Association Taskforce On Radioiodine et al., 2011; HAYS, 1993; 
Matovic, 2013; Matovic et al., 2009; Pacilio et al., 2005; Release of Patients After 
Radionuclide Therapy, 2009; Remy et al., 2008; Willegaignon et al., 2006). 
Disadvantages of RAI therapy includes anxiety, inconvenience and other 
psychological burden due to isolation, lack of isolation room to cater increasing 
number of DTC cases every year, restricted daily activity with family, friends and 
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public for 8 days. Female patients who received RAI therapy shall delay the 
pregnancy for at least 6 months and stop breastfeeding 2 months before and 
discontinue for good after the treatment. This precaution is to prevent I-131 in the 
milk from reaching the infant, as well as to limit the radiation of breast tissue (Lee 
and Park, 2010; Release of Patients After Radionuclide Therapy, 2009).  
Complications of I-131 can be divided into two – early and late. Early 
complications include sialadenitis, exacerbation of exophthalmos, xerostomia, 
tumour swelling, radiation thyroiditis, gastritis, nausea and vomiting. Late 
complications are transient infertility in male, chronic sialadenitis and xerostomia, 
radiation cystitis, agranulocytosis, secondary malignancy and pulmonary fibrosis 
(The Pathophysiologic Basis of Nuclear Medicine, 2006; Ziessman et al., 2013)          
 
     1.2 Malaysian scenario 
There were 21,773 cancer cases were reported among Malaysians in 
Peninsular Malaysia in the year 2006 with incidence rate of 131.3 per 100000 of 
population. Among all cancers, thyroid carcinoma was placed in 6th position of most 
common cancer after breast, colorectal, lung, cervix and ovary carcinoma, which 
comprises 4.1% of all cancer cases registered in Malaysia. (MALAYSIAN CANCER 
STATISTICS 2006 - DATA AND FIGURE PENINSULAR MALAYSIA, 2006). 
According to the latest 2007-2011 Malaysia Cancer Registry Report, DTC were 
ranked ninth and seventeenth for female and male respectively among all 
malignancy in Malaysia (Azizah Ab M, 2016). 
Based on retrospective study in Hospital Kuala Lumpur from 1995 to 2000, 
total numbers of thyroid cancer were 107 cases (Abdullah, 2002). Differentiated 
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thyroid cancer accounted for 91.5% of all thyroid cancer (98 cases) with papillary 
thyroid cancer as the main histological variant (74 cases). 
Almost similar study was done by pathology department of Hospital Universiti 
Sains Malaysia (HUSM) from 1994 to 2004 involving 1486 specimens (Nor Hayati 
Othman, 2009). It was reported that thyroid cancer incidence of all thyroid nodule 
cases was as high as 28.1%. Papillary thyroid cancer was the most common thyroid 
malignancy (76.6%). Median age of thyroid nodule was 40.0 years with female to 
male ratio 6:1. 
Currently, there are 24 nuclear medicine centres (Ministry of Health, university 
and private hospital) in Malaysia but only 9 centres are providing radioactive ablation 
for thyroid cancer. The commonly given activity to the patient ranging from 1.1GBq to 
7.4GBq (30-200mCi) based on risk stratification of the patient. Instead of giving 
empirical (fixed) I-131 dose, personalised dose approach based on I-131 dosimetry 
has become more popular in other countries. However, there is only one centre in 
Malaysia (National Cancer Institute in Putrajaya) using dosimetry as reference to 
appropriate doses to the patient. 
Atomic Energy Licensing Act 1984 (Act 304) has stated that patient shall be 
discharged from isolation once the external dose rate falls below 50µSv/H (Atomic 
Energy Licensing Act 1984). There is variance in period of isolation for I-131 ablation 
patients among nuclear medicine centres based on theirs’ standard of procedure. 
The current isolation period in Hospital Kuala Lumpur for TSH withdrawal patient is 
4-5 days whereas for patient with recombinant TSH (Thyrogen) is 3 days.  
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CHAPTER TWO 
LITERATURE REVIEW 
            Radiation hazard emitted from unsealed source of radionuclide that has been 
administered patients has been a cause of concern to the public. Alpha and beta 
emitters have short travel distance and deposit all their energies within patient’s 
body. The only way radiation hazard can occur is by poor handling of patient’s body 
fluid and excreta, which attribute to <10% of radiation hazard to the public. 
Meanwhile, gamma and x-rays have low energy transfer to the soft tissue and being 
emitted outside patient’s body. The amount of radiation received by public is 
depends on the types and amount of energy emitted, half-life and biokinetic of 
radionuclides; retained radioactivity in the body; distance and duration of exposure  
(American Thyroid Association Taskforce On Radioiodine et al., 2011; Poon et al., 
2016; Release of Patients After Radionuclide Therapy, 2009). 
                As mentioned before, I-131 does not only emitting beta particle, it is also 
emitting high energy gamma (364KeV). Historically, the patient isolation is based on 
physical half-life of the radionuclide substances. This method has been proven to be 
inaccurate and causing unnecessary difficulties to the patient and high cost to the 
health service. The best way to estimate isolation period is by using effective half-
life. Physical half-life is the time needed for the radionuclide to achieve half of the 
initial activity during its decay to stable nuclide. Biological half-life is the time needed 
for the radioactive substance to reach half of its initial value by biological elimination. 
Effective half-life is the time needed for the radionuclide deposited in the living 
organism to reach half of its initial value by the combined action of physical and 
biological decay.  
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           There are 3 methods used to estimate effective half-life of radionuclide (Remy 
et al., 2008; Thomas et al., 1980): 
1. Measurement of urine iodine (urine assay) as retained body activity (RBA). 
2. External dose rate (EDR) using ionising chamber survey meter. 
3. Dosimetry calculation based on I-131/I-123 diagnostic WBS prior ablation. 
 
          Only the first two were implemented as rules and regulations to determine 
period of isolation. In Turkey, 83 patients were recruited to establish connection 
between RBA and EDR and to determine duration of isolation (Demir et al., 2013). 
The monitoring of RBA and EDR were lasted for 5 days. The estimated effective 
half-life was 18.4 hours for EDR and 18.7 hours for RBA. Similar study was done in 
China involving 70 patients (Zhang et al., 2014). Both studies conclude that there 
was strong positive correlation between EDR and RBA and no significant difference 
in period of isolation by using either methods. EDR is proven to be safe, simple and 
reliable method.     
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Calculation formula to determine I-131 effective half-life (Krane, 2008): 
A = A0.e-lt  
 
 
The half-life, t1/2, is defined as follows: 
 
 
 
t1/2 (effective half life) =  
Calculation formula to determine biological half-life: 
 
Biological half life =  
 
 
A = current radioactivity 
A0 = initial radioactivity 
λ = decay constant 
t = half life 
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International Basic Safety Standard (BSS), European Commission, National 
Council on Radiation Protection and Measurement (NCRP), International Atomic 
Energy Agency (IAEA) and International Commission on Radiological Protection 
(ICRP) have set up radiation dose limit to the public into two groups; family 
members/close friends and third person (Table 2.1) (Beckers, 1997; Commission, 
1998; Release of Patients After Radionuclide Therapy, 2009) 
 
Table 2.1 Dose limit to the public based on IAEA and ICRP recommendation 
(Source: Release of patients after radionuclide therapy; Safety Report Series 
No. 63) 
Type of person Dose constraint (mSV) 
1. Third person 
 
0.3/episode 
2. Family members/close friends 
 
• Pregnant women 
 
• Children up to 2 years 
 
• Children 3-10 years old 
 
• Children 11 years old 
up to 60 years old 
 
• Adult older than 60 
years old. 
 
• Comforter/Carer 
 
 
1/year 
1/year 
1/episode 
3/episode 
 
15/episode 
5/episode 
: 
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Comforter/carer is an adult who assists, supports and provides comfort to 
patient and willingly accepts exposure to radiation after appropriate explanation by 
medical staff. It can be a single person, two or more. 
Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) have 
put out regulations that state the restricted dose to the public is 1mSv/year and  
<5mSv/treatment episode for carer/comforter (Recommendations for the Discharge 
of Patients Undergoing Treatment with Radioactive Substances, 2002; Vetter, 1997). 
Radiation restriction in the United State of America is less stringent and simple 
compared to the others. According to the United State Nuclear Regulatory 
Commission (NRC), the effective dose to public either family member, comforter or 
third person must be less than 5mSv/year (American Thyroid Association Taskforce 
On Radioiodine et al., 2011; North et al., 2001; Release of Patients After 
Radionuclide Therapy, 2009) 
            Based on the recommendations above, countries over the globe developed 
their own nuclear regulation by considering many aspects and factors such as health 
status, socioeconomic background, domestic activity, home circumstances, waste 
disposal and health facilities. As a result, the radiation limit and isolation period are 
varied and not harmonised (Table 2.2) (Beckers, 1997; Demir et al., 2013; Lee and 
Park, 2010; Nantajit et al., 2015; Pacilio et al., 2005; Ravichandran et al., 2010; 
Ravichandran, 2014; Recommendations for the Discharge of Patients Undergoing 
Treatment with Radioactive Substances, 2002; Release of Patients After 
Radionuclide Therapy, 2009; Tabei et al., 2012; Venencia et al., 2002; Vetter, 1997; 
Zhang et al., 2014). 
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Table 2.2 Regulation to discharge radio iodinated patient across the globe. 
Country Retain Body Activity    
(MBq) 
 
External Dose Rate (µSv/h) 
USA 
 
Korea 
 
 
<1200 
 
<70 
EU states  
 
 
Germany 
 
Switzerland & 
Austria 
 
Turkey 
 
Poland, Greece, 
Hungary, Italy & 
Sweden 
 
UK, France & 
Belgium 
 
75 to 800, most member 
state 400-600 
 
<75 
 
<170 
 
 
<400 
 
 
<600 
 
 
<800 
 
 
 
<3.5 
 
<10 
 
 
<20 
 
 
<25 
 
 
<40 
Malaysia, 
Thailand & 
Argentina 
 
<1100 <50 
Australia 
 
<600 
 
<25 
Japan 
 
<500 
 
 
China 
 
<400 
 
<20 
 
Oman & Iran <170 
 
<10 
 
IAEA 
recommendation 
<1100 <50 
ETA 
recommendation 
<800 <40 
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According to the local rules, all patients who received I-131 treatment either 
for thyrotoxicosis or thyroid cancer in Germany must be hospitalised at least for 2 
days (Release of Patients After Radionuclide Therapy, 2009). Thyroid cancer 
patients in France, Argentina, Thailand and Korea are commonly isolated for 2 night 
and 3 days while in Italy the isolation period maybe up to 4 days. 
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CHAPTER THREE 
OBJECTIVES AND HYPOTHESES 
3.1 General objective 
• To establish the ideal isolation period for DTC patients who receive I-131 ablation 
therapy in Hospital Kuala Lumpur. 
3.2 Specific objective 
1. To study the external dose rate (EDR) as function of time. 
2. To estimate effective and biological half-life of radioactive iodine. 
3. To determine isolation period based on I-131 doses. 
4. To evaluate other factors that may contribute to iodine clearance (patient 
related and disease related). 
3.3 Hypothesis Statements 
• Alternate hypothesis: Ideal isolation period for I-131 ablation patient is within 
48 hours. 
• Null hypothesis: Ideal isolation period for I-131 ablation patient is longer than 
48 hours. 
 
 
 
 
 18 
3.4 Rationale of the study 
a) Different culture, climate, dietary and race contribute to the differences in 
iodine metabolism. 
b) The current isolation period of 4-5 days does not reflect Malaysia’s patient 
release regulation (<50µSv), which is higher compared to other countries. 
c) To establish local data regarding period of hospitalisation which shall be 
applied in future practice.  
3.5 Benefit of the study 
If the research hypothesis proves to be true, the followings benefit or impact shall be 
observed: 
1. Increase bed turnover in centre with limited number of bed for isolation, 
hence, it will reduce patient waiting list for I-131 ablation.  
2. It provides patient comfort and convenience by shortening the duration of 
hospitalisation without violating the radiation regulation and causing additional 
harm to the public.  
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CHAPTER FOUR 
Methodology 
4.1 Study Design, Study location and Study Period 
A prospective observational study was carried out in the Department of 
Nuclear Medicine of Hospital Kuala Lumpur from the period of March 2016 till 
December 2017. 
4.2 Study population and sample 
 The reference population in this study was differentiated thyroid carcinoma 
patients who underwent total or completion thyroidectomy in Malaysia. Those who 
were referred to the Nuclear Medicine Department, Hospital Kuala Lumpur for I-131 
ablative therapy was the source population. The study participants were those who 
consented to participate in this study and fulfilled the inclusion and exclusion criteria. 
4.3 Inclusion criteria: 
1. Differentiated thyroid cancer patients post total or near total thyroidectomy 
(papillary, follicular and Hurtle cell carcinoma). 
2. Patients adhered to the I-131 ablation preparation as mentioned below:  
i) Stop thyroxine for a month and stop high iodinated food for 2 weeks. 
ii) No recent iodine contrasted agent (six weeks and below). 
iii) Stop iodine containing medication such as amiodarone 3 months prior to 
ablation. 
3. Patients with adequate TSH stimulation (Serum TSH level >30mU/L). 
4. Patients with good renal function – serum creatinine <110µmol/L. 
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4.4 Exclusion criteria: 
1. Pregnant patient. 
2. Patient who received recombinant human thyroid stimulating hormone 
(Thyrogen). 
4.5 Sample size calculation 
Single Proportion calculation was used to derive the sample size of 164 I-131 
ablation therapy patients. This number provided 95% confidence level, 80% study 
power and 3% precision, as the prevalence of thyroid cancer patients is 4% of all 
malignancies in Malaysia (MALAYSIAN CANCER STATISTICS 2006 - DATA AND 
FIGURE PENINSULAR MALAYSIA, 2006) Appendix A. 
4.6 Statistical analysis 
The patient’s descriptive data were described by mean (standard deviation) or 
median (interquartile range), depending on normally distributed or skewed data. The 
categorical variable was reported as frequency and its percentage. ANOVA test was 
used to test the significant difference in estimated effective half-life clearance of 
radioactive I-131 within time. The difference of I-131 effective half-life between age 
group and gender was assessed using independent sample t-test/ Mann-Whitney U 
test.  
The difference between I-131 doses was measured using one-way ANOVA/ 
Kruskal-Wallis test. Fisher’s exact test was used to determine the association of the 
variables (age group, gender, dosage, race, etc.) with number of days in the ward 
(≤48 hours and >48 hours).  
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For all analyses, p values less than 0.05 were considered statistically 
significant. Analyses were performed using SPSS version 24.0 (SPSS Inc. Chicago, 
Illinois, USA). 
4.7 Variable definition 
a) Differentiated thyroid cancer - 3 histology types: papillary, follicular and Hurtle 
cell. 
b) Age: <45 and ≥45 years based on TNM thyroid cancer staging system.  
• Based on TNM staging, patients are categorised into two groups (<45 
and ≥45 years old. In the first group, there is only 2 stages of thyroid 
cancer (stage I and II) while in the second group, there is 4 stages 
(table 4.1) (Yannello, 2013). Patients in the first group have better 
prognosis compared to the second group. 
c) Gender: female and male. 
d) I31 ablation doses: 80mCi, 100mCi, 120mCi and 150mCi.     
• The I-131 doses given in Nuclear Medicine Department of Hospital 
Kuala Lumpur were based on ATA risk stratification (Table 1.1). 80mCi 
was given to the low risk group, 100mCi to the intermediate risk group 
without evidence of lymph node metastasis, 120mCi to the 
intermediate risk group with evidence of lymph node metastasis and 
150mCi for the high risk group. 
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Table 4.1 Differentiated Thyroid Cancer Staging (Source: 7th edition of the 
AJCC Cancer Staging Manual). 
Differentiated thyroid cancer under 45 years  
Stage I    Any size tumour, located in the thyroid or spread to local lymph 
nodes and tissue. 
Stage II  Any size tumour which has spread to other organs.  
 
Differentiated thyroid cancer 45 years or over  
Stage I         Located only in the thyroid; 2 cm or smaller. 
Stage II  Located only in the thyroid; 2-4cm. 
Stage III  Ø Tumour is larger than 4cm and only in the thyroid bed. 
Ø Any size tumour which has spread outside the thyroid and to 
the central compartment lymph nodes of the neck 
Stage IVA    Ø Any size tumour which has spread to the trachea, 
oesophagus, larynx or laryngeal nerve. 
Ø Any size tumour which has spread to the lateral compartment 
lymph nodes of the neck. 
Stage IVB  Any size tumour which has spread to the spinal column or 
surrounds major blood vessel. 
Stage IVC Any size tumour which has spread to other organs. 
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4.8 Research protocol 
1. The medical officer of Nuclear Medicine Department screened new cases 
from surgical/ENT departments. 
2. All the new cases were discussed with nuclear medicine physicians to decide 
the appropriate dose to patients according to ATA risk stratification every 
Thursday (Table 1.1). 
3. The dose for follow up cases has already been decided during the previous 
clinical visit based on the serum Thyroglobulin level, ultrasound findings and 
whole-body scan imaging. 
4. The patients were contacted and instructed to stop thyroxine for a month and 
food with high iodine content such as seafood, turnip and cabbage for 2 
weeks. 
5. The patients were recruited on the day of admission by the primary 
investigator. 
6. The patients received written information (consent form) concerning I-131 
treatment and radioprotection (Appendix B & C). 
7. The renal profile, TFT, serum TG and anti-TG antibody were taken at the 
clinic. 
8. The I-131 strength was assayed in dose calibrator ‘AtomlabTM 400’ (figure 
4.1). 
9. I-131 was administered to the patients according to their individual doses. 
10.  The patients were instructed to hydrate themselves with copious fluid intake 
in isolation ward. 
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11. EDR were measured using hand held type ionising chamber survey meter 
‘Victorin 451 P’ (figure 4.2) by measuring range 0.1µSv/h to 100µSv/h 
(calibrated annually using Caesium 137).  
12. The radiation exposure was measured by asking the patients to stand 1 meter 
away from the survey meter. 
13. EDR measurements were taken at 6H, 18H, 24H and daily for the next 3 
days. (Current practice only measuring EDR on the day of discharge to make 
sure radiation emitted by patient is below 50µSv). 
14. Patients’ data were collected and analysed using SPSS version 24.0. 
 
 
 
Figure 4.1: Dose calibrator AtomlabTM 400. 
 
